SOTIO is conducting a Phase 1/2 DUET-01 trial (NCT05120271), first-in-human, open-label, multicenter, dose escalation study to assess and determine the recommended Phase 2 dose of BOXR1030 in patients with GPC3+ advanced solid tumors after lymphodepleting chemotherapy. The trial will enroll up to 98 patients with advanced, unresectable hepatocellular carcinoma, squamous cell lung cancer, myxoid/round cell liposarcoma, and Merkel cell carcinoma.